Prediction: Rocket Lab Stock Trades Above $100 Again Before 2029

Rocket Lab's backlog reached a record $2.36 billion at June, up 137% year over year, while Q2 revenue rose 62% to $234 million, led by $189.5 million in space-systems revenue. The article argues RKLB could exceed $100 before 2029, implying a roughly $70 billion valuation on an estimated 700 million post-deal shares, contingent on revenue roughly tripling to $3 billion by 2028 and the Iridium acquisition closing in mid-2027. Key execution risks include Neutron's delayed first launch target, continuing EBITDA losses of $8.8 million in Q2 with a guided $17 million-$23 million loss next quarter, and an already elevated valuation of more than 40x sales at about $74 per share.

Analysis

RKLB is no longer primarily a launch optionality story: its valuation now requires a successful integration of IRDM, sustained space-systems execution, and a credible transition from booked revenue to positive consolidated cash generation. The acquisition can improve revenue visibility and create vertical integration around satellite operations, but it also shifts the company toward a lower-growth, mature communications asset while adding execution and financing risk. The relevant multiple should therefore migrate from a pure-play growth premium toward a blended aerospace/communications multiple unless management demonstrates meaningful cross-sell, procurement, or launch-demand synergies.

Near term, the stock is vulnerable to dilution math and quarterly EBITDA deterioration rather than backlog headlines. A 700m-plus fully diluted share base means each additional equity-funded cost overrun or acquisition materially raises the revenue and margin hurdle needed to support the equity value; the market is likely to punish any reduction in 2027 revenue, launch cadence, or IRDM closing certainty disproportionately. The immediate catalyst path is contract conversion and acquisition approval/closing milestones over 1-3 months; the decisive 6-18 month catalyst is a clean Neutron test campaign followed by repeatable launch operations, not merely a pad rollout.

The contrarian point is that Neutron success may not warrant a SpaceX-like valuation premium. Large constellations increasingly have an internal launch provider and government payloads require demonstrated cadence and mission assurance; a first launch only removes one technical risk, while reusable economics, payload integration, and schedule reliability remain unproven. Conversely, a delayed Neutron schedule could benefit incumbents and alternatives including Northrop Grumman (NOC), Lockheed Martin (LMT) and, privately, SpaceX, as customers prioritize assured access over launch-price promises.

Key Decisions for Investors

• Remain underweight RKLB into the next earnings print; do not chase a rebound absent evidence that quarterly revenue conversion and gross margin offset the guided EBITDA loss. Thesis invalidation: raised 2027 revenue/EBITDA outlook with no incremental equity issuance or material increase in net leverage.
• Use a tactical long IRDM / short RKLB ratio pair through the expected mid-2027 closing only after confirming exchange ratio, collar terms, and regulatory timetable. IRDM offers deal-spread exposure while short RKLB hedges the acquirer’s execution, dilution, and launch-risk premium; exit if the spread narrows below a compensation level consistent with closing risk.
• For investors requiring launch upside, wait for a defined Neutron test milestone and buy RKLB only on confirmation of first-launch timing plus funded capex through that event. A failure to maintain the stated schedule or a material cost revision should trigger a hard exit; the stock’s valuation leaves limited tolerance for a multi-quarter delay.
• Monitor NOC and LMT contract awards in national-security launch and satellite programs over the next 6-12 months. Incremental awards to incumbents during a Neutron delay would reinforce a relative long NOC or LMT versus RKLB position, as mission-assurance demand can shift before RKLB’s launch economics are proven.